Furthermore, it has been suggested that treatment with hydralazine and valproic acid enhances the effects of immunotherapy in cancer by regulating the expression of certain molecules, such as HLA class-I, Fas and MIC-A/-B, in tumor cells [44, 45]. This evidence concerns the gene FAS and cancer.